Clinical Trial Detail

Clinical Trials

Clinical Trial Detail

The OLYMPUS Study - Optimized DeLivery of Mitomycin for Primary UTUC Study (Olympus)

Complete title: A Phase 3 Multicenter Trial Evaluating the Efficacy and Safety of MitoGel(TM) on Ablation of Upper Urinary Tract Urothelial Carcinoma

Research Study Number 20162686
 
Principal Investigator John Gore
 
Phase III

Research Study Description

The study is investigating the ability of UroGen's MitoGel™ procedure to treat urothelial carcinoma tumors from the upper urinary tract. If this treatment will prove to be effective this will lead to the development of a new treatment approach for patients suffering from Low Grade Upper Urinary Urothelial Carcinoma (UTUC).

Eligibility Criteria (must meet the following to participate in this study)

** For Eligibility information, please click on the "LOOK UP TRIAL AT NIH" link above. **

Other eligibility criteria may apply.

Research Study Number 20162686
 
Contact John Gore
 
Telephone 206/667-7004
 
E-mail
 

Keywords: Solid Tumors; Neoplasms, Glandular and Epithelial; Carcinoma; Carcinoma, Transitional Cell

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials